Photo of Nancy L. Haigwood, Ph.D.

Nancy L. Haigwood Ph.D.

  • (503) 346-5005
    • Professor Oregon National Primate Research Center
    • Director Oregon National Primate Research Center
    • Molecular Microbiology and Immunology Graduate Program School of Medicine
    • Program in Molecular and Cellular Biosciences School of Medicine

Following completion of her postdoctoral training, Dr. Haigwood spent 17 years in the biotechnology and pharmaceutical sector, principally at Chiron Corporation (Novartis) in Emeryville, California, and at the Bristol-Myers Squibb Pharmaceutical Research Institute in Seattle, Washington.  From 1997-2007, she was a Professor of Microbiology and Pathobiology at the University of Washington and Member at the Center for Infectious Disease Research, both in Seattle. Since 1986, the focus of her research has been on HIV and AIDS, with a focus on halting mother to child transmission and on vaccines for children and adults. She was recruited to OHSU in 2007 to become the fifth director of the Oregon National Primate Research Center and to continue an active research program. Currently, Dr. Haigwood serves as a volunteer board member for the local AIDS service organization in Portland, the Cascade AIDS Project. She is an advocate for science education and outreach to the public and frequently speaks both locally and nationally on this subject.

Areas of interest

  • HIV and AIDS
  • Mother to child transmission of HIV
  • Nonhuman primate models for human disease
  • Antibody-based therapies for infectious diseases
  • Viral vaccines
  • Viral pathogenesis and immunity

Education

  • Ph.D., University of North Carolina at Chapel Hill United States 1980
  • Fellowship:

    • Postdoctoral fellowship, Johns Hopkins University, 1979-1981

Honors and awards

  • Fellow of the American Academy of Microbiology
  • Australasian Society for Immunology Visiting Speaker
  • Cascade AIDS Project 2017 Action Award in recognition of outstanding volunteer service to this AIDS service organization

Memberships and associations

  • Associate Editor, Journal of Virology 2000-2016
  • Editorial Board, AIDS, 2009-10 and 2016-present
  • Office of AIDS Research Advisory Council, 2002-2005
  • US-Japan Cooperative Medical Science Program (AIDS panel); retired U.S. Chairman, 2003-10
  • Board of Scientific Counselors, NCI, NIH 2006-2008
  • Scientific Advisory Committee, International AIDS Vaccine Initiative, 2007-2012
  • Council of Councils, NIH 2013-2015
  • National Association for Biomedical Research, Executive Board 2013-2016
  • Board of Scientific Counselors, Vaccine Research Center, NIAID, NIH 2011-present

Publications

  • Steimer, KS, CJ Scandella, PV Skiles, and NL Haigwood (1991) Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to gp120.  Science 254:105-108.

  • Igarashi T, C Brown, A Azadegan, N Haigwood, M Martin, and R Shibata. (1999) Human immunodeficiency virus type 1 neutralizing antibodies facilitate clearance of cell-free virions from blood plasma. Nature Medicine 5:211-216.

  • Shibata R, T Igarashi, N Haigwood, A Buckler-White, R Ogert, W Ross, R. Willey, MW Cho, and MA Martin (1999) Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nature Medicine 5:204-210.

  • Ng CT**, Jaworski JP***, Jayaraman P**, Sutton WF, Delio P, Kuller L, Anderson D, Landucci G, Richardson BA, Burton DR, Forthal DN, Haigwood NL. (2010) Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nature Medicine 16(10):1117-9.

  • Malherbe, D***, N Doria-Rose***, L Misher, T Beckett**, W Blay Puryear***, JT Schuman, Z Kraft, J O’Malley, M Mori, I Srivastava, S Barnett, L Stamatatos and NL Haigwood. (2011) Sequential immunization with a subtype B HIV-1 Envelope quasispecies partially mimics the in vivo development of neutralizing antibodies. J Virology, 85: 5262-74.

  • JP Jaworski***, Z Brower, EJ Leon, DC Malherbe***, G Landucci, WF Sutton, B Guo, F Engelmann, B Zheng, A Legasse, B Park, M Dickerson, AD Lewis, LMA Colgin, M Axthelm, I Messaoudi, J Kobie, JB Sacha, DR Burton, DN Forthal, AJ Hessell, and NL Haigwood (2013) Passive neutralizing antibodies alter the dynamics of infection and enhance survival of SHIVSF162P3-infected infant rhesus macaques, J Virol 87: 10447-59.

  • Krebs, SJ***, SP McBurney***, DN Kovarik**, CD Waddell, JP Jaworski***, WF Sutton, MM Gomes***, M Trovato, G Waagmeester, SJ Barnett, P DeBerardinis, NL Haigwood (2014) Multimeric scaffolds displaying the HIV-1 Envelope MPER induce MPER-specific antibodies and cross-neutralizing antibodies when co-immunized with gp160 DNA. PLoS One 9: e113463. PMCID: 4267727.

  • Hessell AJ, DC Malherbe, F Pissani** SP McBurney***, SJ. Krebs***, M Gomes***, S Pandey, WF Sutton, BJ Burwitz, M Gray, H Robins, B Park, JB Sacha, CC LaBranche, DH Fuller, DC Montefiori, L Stamatatos, DN Sather|, and NL Haigwood (2016) Achieving potent autologous neutralizing antibody responses against Tier 2 HIV-1 viruses by strategic selection of Envelope immunogens, Journal of Immunology 196: 3064-78.

  • AJ Hessell, JP Jaworski***, E Epson***, K Matsuda, S Pandey, C Kahl, J Reed, WF Sutton, KB Hammond, TA Cheever, PT Barnette, A Legasse, S Planer, J Stanton, A Pegu, X Chen, K Wang, MK Axthelm, A Lewis, VM Hirsch, BS Graham, JR Mascola, JB Sacha, and NL Haigwood (2016) Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. Nat Medicine 22: 362-8.

  • A Pegu, AJ Hessell, JR Mascola, NL Haigwood (2017) Use of broadly neutralizing antibodies for HIV-1 prevention. Immunological Reviews 275 (1), 296-312.

Edit profile